Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28936560 | 0.87 | MEN1 (0.48) | KMT2AMEN1SMN1; SMN2ALDH1A1RECQL | |
| SCHEMBL10088128 | 0.84 | CASP2 (0.53) | SMN1; SMN2ALDH1A1CASP2NAAAHPGD | |
| SCHEMBL21261777 | 0.83 | ALDH1A1 (0.43) | KMT2AMEN1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL14217283 | 0.82 | MEN1 (0.63) | KMT2AMEN1SMN1; SMN2RECQLCASP2 | |
| SCHEMBL20900404 | 0.82 | MEN1 (0.63) | KMT2AMEN1SMN1; SMN2RECQLCASP2 | |
| SCHEMBL10088105 | 0.82 | LMNA (0.44) | KMT2AMEN1ALDH1A1CASP2HPGD | |
| SCHEMBL21881728 | 0.81 | CYP2D6 (0.46) | KMT2ASMN1; SMN2ALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL14086890 | 0.80 | KMT2A (0.71) | KMT2AMEN1SMN1; SMN2ALDH1A1RECQL | |
| SCHEMBL10359007 | 0.79 | FAAH (0.53) | KMT2AMEN1SMN1; SMN2CASP2NAAA | |
| SCHEMBL16140111 | 0.79 | SLC1A3 (0.50) | ALDH1A1SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975089-B2 | Radiopharmaceuticals, radioimaging agents, and uses thereof | Clarity Pharmaceuticals Ltd (AU) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975089-B2 | Radiopharmaceuticals, radioimaging agents, and uses thereof | SLC30A5, SLC40A1, FOLH1 | KMT2A 1151/4885MEN1 184/4885SMN1; SMN2 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.